| MCK |
Report |
Adjusted EPS |
BEAT |
pred ~$9.78 vs. cons $9.56 |
MEDIUM |
| MCK |
Report |
Revenue |
IN-LINE |
pred ~$103.6B vs. cons $103.88B |
MEDIUM |
| MCK |
Report |
Oncology & Multispecialty adjusted operating profit |
BEAT |
pred ~$354M vs. cons $347M |
MEDIUM |
| MCK |
Guide |
Adjusted EPS |
BETTER |
guide ~$44.50 midpoint vs. cons $44.29 (FY2027) |
MEDIUM |
| MCK |
Guide |
Adjusted operating-profit growth |
BETTER |
guide ~10.5% midpoint vs. cons 10.0% (FY2027) |
LOW |
| MCK |
Guide |
Free cash flow |
UNCHANGED |
guide ~$4.70B midpoint vs. cons $4.70B (FY2027) |
MEDIUM |
| MCK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.1% |
— |
MEDIUM |
| MCK |
Return |
5-day cumulative residual |
+4.2% (FOLLOW-THROUGH) |
A predicted ~$0.22 Q1 EPS beat versus consensus and a ~$0.30 increase in the FY2027 guidance midpoint leave roughly $0.08 of positive out-period math, supporting modest estimate revisions and follow-through rather than a fade. |
MEDIUM |